All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Court Dissolves Schering-Plough Consent Decree

August 9, 2007
By Michelle Hoffman
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

Schering-Plough announced today that a consent decree filed against the company in May, 2002, had been dissolved by the US District Court for the District of New Jersey in Newark.

Kenilworth, NJ (Aug. 2)-Schering-Plough announced today that a consent decree filed against the company in May 2002, had been dissolved by the US District Court for the District of New Jersey in Newark. The consent decree of permanent injunction enjoined the company from manufacturing, packaging, or distributing some 42 products in its Kenilworth and Union, New Jersey, plants and another 13 products in its plants in Manati and Las Piedras, Puerto Rico, because of violations of US Food and Drug Administration’s good manufacturing practices. The company, then under the direction of CEO Richard J. Kogan, was also directed to recall and destroy all lots of Theophylline and Proventil Repetabs in the United States that were still within their labeled expiration periods. Finally, the government levied stiff fines against the company totaling $500 million.

On January 3, 2006, the company announced it had completed all of the 212 significant steps and the 30 validation actions set out by the decree. At the time, the company petitioned the government to dissolve the decree and allow them to reopen the plants.

In a statement issued through a company press release, Fred Hassan, Schering-Plough’s chairman and CEO responded to the dissolution by saying, “This is an important milestone for Schering-Plough as we continue to put issues of the past behind us and make further progress on our Action Agenda. Schering-Plough colleagues have worked hard to establish continuous quality improvement and compliance as part of our culture. In turn, we have been working diligently to earn the trust of our stakeholders. Ensuring quality in our products and systems underpins everything we do.”

Recent Videos
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Behind the Headlines, Episode 18
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content

ADELAIDE, SOUTH AUSTRALIA. - On November 15, 2018. – The University of South Australia is a public university, it is main campus is located on North Terrace in the Adelaide city centre | Image Credit: © arliftatoz2205 - stock.adobe.com

Why You Should Know About a New Weekly Injectable for Parkinson’s

Christopher Cole
July 15th 2025
Article

Biodegradable weekly implant delivers stable levodopa levels, aiming to streamline Parkinson’s care while reshaping drug reformulation and delivery strategies.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | Image Credit: © Tada Images - stock.adobe.com

FDA Publishes More Than 200 Complete Response Letters

Christopher Cole
July 11th 2025
Article

FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.


Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.


Brain Injury, Blood in Injured Brains (stroke, brain hemorrhage, intracerebral hemorrhage, subarachnoid hemorrhage, arteriovenous malformation, brain aneurysm rupture, traumatic brain injury) | Image Credit: © Arugula Pica - stock.adobe.com

Generative AI-Driven Collaboration to Research Treatments for Brain Hemorrhage Complications

Patrick Lavery
July 9th 2025
Article

Delayed cerebral ischemia is a leading complication in the severe form of stroke known as subarachnoid hemorrhage and can result in long-term neurological damage, disability, or death.


Bone structure 3d illustration, normal and with osteoporosis | Image Credit: © adimas - stock.adobe.com

Theramex Treatment for Osteoporosis in Postmenopausal Women Accepted by Scottish Medicines Consortium

Patrick Lavery
July 7th 2025
Article

The company estimated that more than 1000 women in Scotland at very high risk of fracture would be eligible for treatment.

Related Content

ADELAIDE, SOUTH AUSTRALIA. - On November 15, 2018. – The University of South Australia is a public university, it is main campus is located on North Terrace in the Adelaide city centre | Image Credit: © arliftatoz2205 - stock.adobe.com

Why You Should Know About a New Weekly Injectable for Parkinson’s

Christopher Cole
July 15th 2025
Article

Biodegradable weekly implant delivers stable levodopa levels, aiming to streamline Parkinson’s care while reshaping drug reformulation and delivery strategies.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | Image Credit: © Tada Images - stock.adobe.com

FDA Publishes More Than 200 Complete Response Letters

Christopher Cole
July 11th 2025
Article

FDA says the move boosts regulatory transparency, offering insights into common approval barriers in drug applications and reducing guesswork.


Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.


Brain Injury, Blood in Injured Brains (stroke, brain hemorrhage, intracerebral hemorrhage, subarachnoid hemorrhage, arteriovenous malformation, brain aneurysm rupture, traumatic brain injury) | Image Credit: © Arugula Pica - stock.adobe.com

Generative AI-Driven Collaboration to Research Treatments for Brain Hemorrhage Complications

Patrick Lavery
July 9th 2025
Article

Delayed cerebral ischemia is a leading complication in the severe form of stroke known as subarachnoid hemorrhage and can result in long-term neurological damage, disability, or death.


Bone structure 3d illustration, normal and with osteoporosis | Image Credit: © adimas - stock.adobe.com

Theramex Treatment for Osteoporosis in Postmenopausal Women Accepted by Scottish Medicines Consortium

Patrick Lavery
July 7th 2025
Article

The company estimated that more than 1000 women in Scotland at very high risk of fracture would be eligible for treatment.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.